Effusions are large buildups of fluid and can be present in many cancer patients, including those with mesothelioma. Peritoneal effusion is a common symptom of peritoneal mesothelioma that has been reported in 60 – 100% of diagnosed mesothelioma cases.
Normally, a small amount of lubricating fluid is found in the peritoneum. But when peritoneal effusion develops, the level of peritoneal fluid increases, leading to uncomfortable symptoms like abdominal swelling. Malignant mesothelioma patients experiencing peritoneal effusions may have a less favorable prognosis, as the condition can indicate a more advanced stage of disease. However, there are treatments available to remove the surplus fluid and provide symptom relief.
What Is Peritoneal Effusion?
Fluid can naturally be found in the peritoneum to lubricate the tissues and linings of organs within the abdominal cavity. On average, women in good overall health have more peritoneal fluid than healthy men, which can also fluctuate with the menstrual cycle. However, abnormal amounts of intraperitoneal fluid may develop as a symptom of mesothelioma or other health conditions.
Peritoneal effusion, also referred to as ascites, is a condition that causes fluid to build up between the layers of the peritoneum within the abdominal cavity. It can develop from highly active cancers, like mesothelioma, that produce excess fluid that accumulates in the abdominal cavity. Blocked lymph nodes, a sign of more advanced disease, may also trigger peritoneal effusion. The effusion can either be malignant or benign.
More than 85% of all ascites are the result of cirrhosis of the liver, though up to 10% develop in cancer patients. They are most common in patients with peritoneal surface malignancies such as ovarian, uterine, breast, pancreatic, liver and lung cancers. The symptom has also been identified in the majority of peritoneal mesothelioma cases. Patients with peritoneal mesothelioma, which develops after inhalation or ingestion of asbestos fibers, typically present with either abdominal pain and no peritoneal effusion or experience no abdominal pain, but have both peritoneal effusion and abdominal distension or swelling.
Diagnosing the Symptoms of Peritoneal Effusions
Peritoneal effusions are a symptom of a larger illness themselves and can emerge for a number of reasons, each of which can bring about different associated symptoms. For instance, malignant peritoneal mesothelioma patients may experience effusions coupled with bowel obstruction, weight loss and fever. The severity of symptoms may increase as more fluid collects within the peritoneal cavity.
- Ankle or leg swelling
- Chest pain
- Difficulty breathing
- Loss of appetite
- Pain or swelling of the abdomen
- Weight gain
After a patient presents with symptoms, an abdominal ultrasound is often used to diagnose the ascites. For mesothelioma patients, imaging tests like an X-ray or a CT scan (computed tomography) may also be used to confirm the presence of peritoneal effusion. When diagnosing peritoneal mesothelioma, a doctor can see several presentations on the CT scan. For patients who have developed ascites, researchers may refer to the appearance on the scan as the “wet type.” This presentation indicates excess abdominal fluid, swelling of the intestines and small nodules in the organs. Peritoneal mesothelioma patients with ascites may also present as the “mixed type” on their scan, meaning they have developed ascites and may have large tumors that are common with the “dry type” presentation seen on some CT scans.
In addition to imaging scans, a fluid wave test may be used to identify the ascites if there is substantial fluid retention within the abdominal cavity. The test relies on placing pressure on the abdomen and tapping the area to monitor a ripple effect from one side of the abdomen to the other. A peritoneal effusion and ascitic fluid build up is present if the ripple from the tapping can be felt on the other side of the abdomen.
Diagnosing ascites is an important first step in pinpointing the underlying condition causing the fluid build up. Patients may first see a gastrointestinal specialist before the underlying cause is identified. Once ascites have been identified, a doctor will likely take a biopsy, or fluid sample. Through pathology tests, they can confirm whether the fluid is malignant or benign, as well as identify the cause of the symptom. For mesothelioma patients, a biopsy of fluid or tissue samples is the only way to confirm the cancer’s presence.
Prognosis of Peritoneal Effusions
Patients who develop malignant peritoneal effusions generally have a less favorable prognosis and lower survival rates than those without the symptom because it indicates a more advanced stage of mesothelioma. Typically patients only live between one and four months following their diagnosis.
Overall, malignant peritoneal mesothelioma is the second most common form of the cancer with an average life expectancy of six months to one year. An individual’s prognosis can differ based on their age, gender and overall health. Though the presence of peritoneal effusion may signal a later stage of disease and a worse prognosis, patients may still be able to seek treatment to alleviate symptoms and possibly extend survival time.
Depending on the condition causing the peritoneal effusion, patients may have a number of treatment options. For mesothelioma patients, a palliative treatment plan may be recommended to reduce the fluid buildup and relieve associated symptoms. A paracentesis is among the most common treatments. A paracentesis is a palliative surgery that uses a hollow needle and drainage tube to remove excess fluid. This procedure may be done on more than one occasion to provide symptom relief. In some cases, patients have also seen relief through another procedure called peritoneovenous shunt placement, which moves fluid out of the abdomen and back into the veins.
Additionally, treating symptoms palliatively through the use of catheters has shown promise for mesothelioma cancer patients with ascites. One retrospective study analyzed results from 20 cancer patients experiencing peritoneal ascites. The researchers found that a peritoneal catheter was a useful and minimally invasive palliative option for the patients, with a success rate of at least 95.2%. Patients had a median survival time of 27 days following placement of the catheter, making this an encouraging palliative option for patients with late-stage mesothelioma.
In addition to palliative treatments for relieving the fluid buildup in the abdomen, patients may also undergo curative treatment options for mesothelioma that can reduce ascites. Depending on a patient’s specific case, one of the most effective peritoneal mesothelioma treatment options is cytoreductive surgery to remove as much of the tumors as possible combined with a heated chemotherapy wash called hyperthermic intraperitoneal chemotherapy or HIPEC. Research has shown this treatment can extend life expectancy to five years or longer for some patients, though it likely will not be a viable option for those with advanced stage mesothelioma.
Chemotherapy, another common peritoneal mesothelioma treatment, has also been shown to help relieve pressure from the ascites by reducing the production of peritoneal fluid. When the chemotherapy kills the cancer cells, they stop fluid production, which in turn reduces the pressure being felt by patients. However, it might not be a viable option for patients with more advanced mesothelioma as they may not be able to withstand the side effects. Patients may also elect to participate in clinical trials to take advantage of up-and-coming treatment options.
Any individual who has known asbestos exposure or experiences any mesothelioma symptoms should talk to a doctor right away. Early detection of the disease may prevent ascites from developing and help doctors determine the best treatment plan for extending survival.
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Ahmed F, Koulaouzidis A. Malignant peritoneal mesothelioma as a rare cause of ascites: a case report. Journal of Medical Case Reports 2008. April 2008; 2:121. doi: 10.1186/1752-1947-2-121
Bridda A, Padoan L. Peritoneal Mesothelioma: A Review. MedGenMed: Medscape General Medicine. May 2007; 9(2): 32.
Brook I, Altman RS, et al. Measurement of lactate in ascitic fluid: an aid in the diagnosis of peritonitis with particular relevance to spontaneous bacterial peritonitis of the cirrhotic. Digestive Diseases and Science. December 1981; 26(12):1089-94.
Cancer Research UK. Treating fluid in the abdomen. Updated August 2018.
Centers for Disease Control and Prevention. Assessment for Ascites. Dengue Clinical Case Management E-learning.
Cleveland Clinic. Portal Hypertension. November 2017.
Gupta R, Misra S, et al. Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. Journal of Gastroenterology and Hepatology. May – June 1995; 10(3):295-9.
Kepenekian V, Elias D, et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. European Journal of Cancer. September 2016; 65:69-79. doi: 10.1016/j.ejca.2016.06.002
Kistler A. Malignant Ascites: Diagnosis and Management. Cancer Therapy Advisor. April 2015.
Meier M, Mortensen F, et al. Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter. Acta Radiologica Open. July 2015; 4(7): 1-7. doi: 10.1177/2058460115579934
Nabili S. Ascites. MedicineNet. August 2017.
National Cancer Institute. Malignant Peritoneal Effusion. NCI Dictionary of Cancer Terms.
Shah R, Fields J, et al. Ascites. Medscape. December 2017.
Sangisetty S, Miner T. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World Journal of Gastrointestinal Surgery. April 2012; 4(4):87-95. doi: 10.4240/wjgs.v4.i4.87